PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor
OZTx, with the aim of social implementation of cell therapy products and innovative iPS cell-related technologies (platform innovation), is conducting research and development of regenerative medicine using iPS cell-derived cardiomyocytes and islet cells and supports commercialization of development candidate seeds through collaboration with commercial partnerships and academic institutions.